Does in vitro bone marrow purging improve the outcome after autologous bone marrow transplantation?
High-dose therapy with bone marrow rescue is now regarded as an effective treatment for a variety of malignancies. In an attempt to circumvent the scarcity of HLA-matched donors, autologous marrow has been successfully used as the source of cells for hematopoietic reconstitution. There has been considerable controversy as to whether any malignant cells present in the graft could contribute to relapse of disease post-transplant. In this paper we review clinical results obtained by using autologous transplantation and present evidence on how ex vivo tumor purging may contribute to the outcome.
Lazarus
H M
HM
Department of Medicine, Ireland Cancer Center of the University Hospitals of Cleveland, Case Western Reserve University, OH.
Rowe
J M
JM
Goldstone
A H
AH
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000401:mortality / Q000706:statistics & numerical data; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D015993:Life Tables; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D009447:Neuroblastoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents